Qiagen N.V. Common Shares (NY:QGEN)

44.75 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

August 05, 2025

From QIAGEN N.V.

Via Business Wire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Look at Qiagen's Upcoming Earnings Report ↗

August 04, 2025

Via Benzinga

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

July 22, 2025

From QIAGEN N.V.

Via Business Wire

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

QIAGEN N.V. (NYSE:QGEN) - A Strong Technical Setup for Breakout Investors ↗

July 21, 2025

QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance...

Via Chartmill

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

July 08, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

June 26, 2025

From QIAGEN N.V..

Via Business Wire

QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering ↗

June 26, 2025

QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors.

Via Chartmill

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

June 18, 2025

From QIAGEN N.V.

Via Business Wire

Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗

June 16, 2025

Stifel also upgraded the stock to ‘Buy’ with a $107 price target.

Via Stocktwits

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

June 02, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals ↗

June 02, 2025

QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors.

Via Chartmill

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 22, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 12, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN announces plans for transition in leadership of Supervisory Board

May 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

May 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

May 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

April 29, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

April 22, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

April 15, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

April 08, 2025

From QIAGEN N.V.

Via Business Wire

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance ↗

April 07, 2025

Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.

Via Benzinga

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

April 06, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

April 06, 2025

Via ACCESS Newswire

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

April 01, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

March 31, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

March 06, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

March 03, 2025

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.